REDWOOD CITY, CA / ACCESSWIRE / March 21, 2024 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, announces it partnership with Health Aid Africa, one of the most highly anticipated charity concerts for healthcare access and awareness.
Experience the rhythm of life like never before at the Health Aid Africa charity concert, where the thrill of music meets the heart of wellness, thanks to a pioneering partnership with Biotricity Inc. Set against the backdrop of the world's most renowned stadium, this event offers more than just spectacular musical acts-it presents a life-saving opportunity. Engage with Biotricity's cutting-edge wearable heart monitors and state-of-the-art diagnostic tools to receive invaluable heart health insights.
This collaboration marks a significant leap forward in making sophisticated cardiac care accessible to all. Join us in a celebration that transcends entertainment, empowering you to connect with your heart's health while losing yourself in the rhythm of inspiring performances. Don't miss this unique blend of exhilaration and enlightenment-your ticket to the concert is also your key to a healthier heart.
The Health Aid Africa concert, a pioneering initiative to fund an innovative hospital equipped with the latest in health technology, promises to bring quality medical care to those in underserved areas. This grand endeavor is led by Eddie Tantoco & Elora Tran of Eye on Channel, Dustin Salinas of Rasha LTD Inc., and Andre Roberson of the Power of One Foundation, showcasing a remarkable blend of healthcare, technology, and philanthropy. Set to take place at the magnificent Allegiant Stadium, with a seating capacity of 65,000, the event is also geared to captivate billions across the globe through live stream and broadcast channels. The production will be enhanced with live-streaming talent cutaways, bridging continents from Africa to Asia, Europe, Australia, Singapore, the UK, and beyond, ensuring a truly global experience. By being part of this monumental event, you're not just witnessing a spectacular showcase of music and technology; you're supporting a noble cause that extends far beyond the concert's final note. Join us in this transformative journey to uplift and provide for those who need it most.
Dr. Jere Rivera-Dugenio of Rasha LTD Inc. will contribute significantly by providing a Rasha dome and the JustGoingViral platform. The Rasha dome will serve as a vital preparatory space for performers, ensuring they are in optimal condition before their stage appearances. The JustGoingViral platform is an integrated business solution powered by the leading marketing tools and AI, guaranteeing that news of the heart health screening initiative reaches a wide audience.
Further amplifying Health Aid Africa's impact, Silicon Valley HQ, will provide free upskilling opportunities - including webinars and mentorship - to empower the next generation of African students and entrepreneurs. SiliconValleyHQ is a virtual ecosystem that provides proprietary startup templates, mentorship access to 150+ experts, industry insights and a virtual acceleration program.
Elevate your brand at the Health Aid Africa concert, a unique blend of music, wellness, and philanthropy. This high-profile event offers your brand unparalleled exposure to millions worldwide and a direct connection with a diverse, engaged audience. By sponsoring, your brand will not only be showcased across global platforms but will also align with a powerful cause, enhancing your corporate image. Participate in interactive booths, product demos, and direct consumer engagement in a vibrant, feel-good environment.
Join us in making a significant impact while placing your brand at the heart of innovation and compassion. Be more than a logo; be a leader in change with https://healthaidafrica.com
For Investors interested in learning more about Biotricity, its robust revenue trajectory, and its comprehensive suite of medical diagnostic and consumer healthcare technologies, visit www.biotricity.com/investors.
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Investor Relations Contacts
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.28 |
Daily Change: | -0.13 -32.43 |
Daily Volume: | 75,985 |
Market Cap: | US$6.830M |
October 03, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB